U.S. Markets for Neurostimulation Products

According to the Society for Neuroscience and the National Institutes of Health, the total annual cost to manage neurologic diseases and injuries in the United States (U.S.) exceeds $400 billion. The most prevalent neurologic disorders in the U.S afflict approximately 170 million people.

Neurostimulation devices are used to treat a number of debilitating conditions affecting the nervous system; implantable systems currently are cleared by the U.S. Food and Drug Administration to treat chronic pain, epilepsy, essential tremor and dystonia, gastroparesis, hearing loss, major treatment-resistant depression, obsessive-compulsive disorder, Parkinson’s disease, and urinary incontinence. Emerging areas of neurostimulation device development include the treatment of large-population diseases/disorders such as Alzheimer’s disease, blindness, chronic migraines, morbid obesity, obstructive sleep apnea, paralysis, stroke, and tinnitus, with the potential to expand to several other applications.

The market analyses provided by this report include forecasts for sales of implantable neurostimulation devices—including cochlear implants and systems for deep brain stimulation (DBS), gastric nerve stimulation (GNS), spinal cord stimulation (SCS), sacral nerve simulation (SNS), and vagus nerve stimulation (VNS)—as well as for transcutaneous electrical nerve stimulation (TENS).

In 2009, the combined U.S. market for neurostimulation products (including implantable neurostimulation devices and TENS systems) was valued at approximately $1,304.0 million; during the forecast period covered by this report, this market is projected to grow at a healthy compound annual rate of 15.9%, reaching an estimated $2,730.4 million in the year 2014.